$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000071913518000055 Filed on August 01, 2018

Income Statement

Concept	2018 Q2	2017 Q4	2017 Q2
Revenue	$3.691M	$3.658M	$2.311M
YoY Change	59.71%	-61.47%	-75.14%
Cost Of Revenue	$1.154M	$960.0K	$4.757M
YoY Change	-75.74%	-79.4%	3.53%
Gross Profit	$2.537M	$2.696M	$1.572M
YoY Change	61.39%	-44.18%	-66.55%
Gross Profit Margin	68.73%	73.7%	68.02%
Selling, General & Admin	$2.213M	$4.050M	$2.929M
YoY Change	-24.45%	-22.12%	44.86%
% of Gross Profit	87.23%	150.22%	186.32%
Research & Development	$763.0K	$340.0K	$696.0K
YoY Change	9.63%	-50.0%	17.57%
% of Gross Profit	30.07%	12.61%	44.27%
Depreciation & Amortization	$172.0K	$170.0K	$178.0K
YoY Change	-3.37%	0.0%	2.89%
% of Gross Profit	6.78%	6.31%	11.32%
Operating Expenses	$5.470M	$4.420M	$6.348M
YoY Change	-13.83%	-24.83%	21.84%
Operating Profit	-$2.933M	-$1.724M	-$1.306M
YoY Change	124.58%	64.19%	156.08%
Interest Expense	$38.00K	$90.00K	$0.00
YoY Change		-84.75%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$8.000K	$0.00	$2.000K
YoY Change	300.0%		-122.22%
Pretax Income	-$2.925M	-$3.140M	-$1.304M
YoY Change	124.31%	582.61%	151.25%
Income Tax	$13.00K	$30.00K	$4.000K
% Of Pretax Income
Net Earnings	-$2.938M	-$820.0K	-$1.308M
YoY Change	124.62%	57.69%	152.02%
Net Earnings / Revenue	-79.6%	-22.42%	-56.6%
Basic Earnings Per Share	-$10.00	-$90.00	-$130.00
Diluted Earnings Per Share	-$10.00	-$24.94K	-$0.04
COMMON SHARES
Basic Shares Outstanding	32.89M shares	32.86M shares	30.86M shares
Diluted Shares Outstanding	32.89M shares		30.86M shares

Balance Sheet

Concept	2018 Q2	2017 Q4	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.900M	$9.900M	$10.30M
YoY Change	-23.3%	-31.72%	10.75%
Cash & Equivalents	$7.875M	$9.949M	$10.29M
Short-Term Investments
Other Short-Term Assets	$1.300M	$1.200M	$1.300M
YoY Change	0.0%	0.0%	0.0%
Inventory	$7.533M	$4.274M	$7.582M
Prepaid Expenses
Receivables	$5.592M	$4.857M	$4.929M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.23M	$22.55M	$24.12M
YoY Change	-7.84%	-15.04%	17.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.314M	$6.033M	$6.240M
YoY Change	1.19%	-6.45%	-4.0%
Goodwill	$185.0K	$185.0K	$185.0K
YoY Change	0.0%	0.0%
Intangibles	$1.510M	$1.510M	$1.510M
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$67.00K	$67.00K	$218.0K
YoY Change	-69.27%	-34.95%	-56.4%
Total Long-Term Assets	$8.426M	$8.441M	$8.436M
YoY Change	-0.12%	-1.52%	-6.27%
TOTAL ASSETS
Total Short-Term Assets	$22.23M	$22.55M	$24.12M
Total Long-Term Assets	$8.426M	$8.441M	$8.436M
Total Assets	$30.65M	$30.99M	$32.56M
YoY Change	-5.84%	-11.74%	9.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.745M	$1.583M	$2.077M
YoY Change	32.16%	-1.43%	15.39%
Accrued Expenses	$2.420M	$861.0K	$2.511M
YoY Change	-3.62%	-66.94%	-3.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$239.0K	$239.0K	$239.0K
YoY Change	0.0%	0.0%	19.5%
Total Short-Term Liabilities	$6.237M	$5.973M	$5.618M
YoY Change	11.02%	13.3%	22.13%
LONG-TERM LIABILITIES
Long-Term Debt	$2.335M	$2.455M	$2.575M
YoY Change	-9.32%	-8.87%	-14.17%
Other Long-Term Liabilities	$0.00	$100.0K	$100.0K
YoY Change	-100.0%	-50.0%	-50.0%
Total Long-Term Liabilities	$2.335M	$2.555M	$2.575M
YoY Change	-9.32%	-5.16%	-19.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.237M	$5.973M	$5.618M
Total Long-Term Liabilities	$2.335M	$2.555M	$2.575M
Total Liabilities	$9.080M	$8.956M	$8.985M
YoY Change	1.06%	0.78%	8.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.70M	-$28.50M	-$26.43M
YoY Change	12.4%	21.6%
Common Stock	$33.00K	$33.00K	$31.00K
YoY Change	6.45%	6.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.57M	$22.03M	$23.57M
YoY Change
Total Liabilities & Shareholders Equity	$30.65M	$30.99M	$32.56M
YoY Change	-5.84%	-11.74%	9.99%

Cashflow Statement

Concept	2018 Q2	2017 Q4	2017 Q2
OPERATING ACTIVITIES
Net Income	-$2.938M	-$820.0K	-$1.308M
YoY Change	124.62%	57.69%	152.02%
Depreciation, Depletion And Amortization	$172.0K	$170.0K	$178.0K
YoY Change	-3.37%	0.0%	2.89%
Cash From Operating Activities	-$570.0K	$740.0K	-$1.070M
YoY Change	-46.73%	-234.55%	872.73%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	-$190.0K	-$80.00K
YoY Change	137.5%	72.73%	300.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	-$190.0K	-$190.0K	-$80.00K
YoY Change	137.5%	72.73%	300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	-60.00K	-60.00K
YoY Change	0.0%	-101.04%
NET CHANGE
Cash From Operating Activities	-570.0K	740.0K	-1.070M
Cash From Investing Activities	-190.0K	-190.0K	-80.00K
Cash From Financing Activities	-60.00K	-60.00K	-60.00K
Net Change In Cash	-820.0K	490.0K	-1.210M
YoY Change	-32.23%	-90.41%	830.77%
FREE CASH FLOW
Cash From Operating Activities	-$570.0K	$740.0K	-$1.070M
Capital Expenditures	-$190.0K	-$190.0K	-$80.00K
Free Cash Flow	-$380.0K	$930.0K	-$990.0K
YoY Change	-61.62%	-311.36%	1000.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
CY2018Q2	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	bvx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	-178000	USD
	bvx	Warrant Exercised Amount WarrantExercisedAmount	95000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1583000	USD
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33203517	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	BOVIE MEDICAL CORP
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2745000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4857000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5592000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2462000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2420000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	447000	USD
CY2018Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	394000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50495000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51244000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	341000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	749000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000	USD
CY2017Q4	us-gaap	Assets Assets	30988000	USD
CY2018Q2	us-gaap	Assets Assets	30654000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	22547000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	22228000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9949000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7875000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15235000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11071000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10668000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8535000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4164000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2133000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33021170	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33055131	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32878091	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32912556	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4757000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8920000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5198000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10124000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	368000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	368000	USD
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	92000	USD
CY2018Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	115000	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	178000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	356000	USD
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	172000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	371000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	20000	USD
CY2018Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	179000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	235000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	185000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	185000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	5042000	USD
	us-gaap	Gross Profit GrossProfit	9268000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	6277000	USD
	us-gaap	Gross Profit GrossProfit	11267000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1304000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2984000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-259000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1183000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	471000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1162000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	355000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	817000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	955000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-128000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-898000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	125000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	72000	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-72000	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-23000	USD
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	126000	USD
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	20000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1507000	USD
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2018Q2	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-36000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-67000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-38000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-72000	USD
	us-gaap	Interest Paid InterestPaid	67000	USD
	us-gaap	Interest Paid InterestPaid	72000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3276000	USD
CY2018Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3301000	USD
CY2017Q4	us-gaap	Inventory Gross InventoryGross	8439000	USD
CY2018Q2	us-gaap	Inventory Gross InventoryGross	9394000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	6526000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	7533000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5163000	USD
CY2018Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	6093000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1913000	USD
CY2018Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1861000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	83000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	-52000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8956000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	9080000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30988000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30654000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5973000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6237000	USD
CY2018Q2	us-gaap	Long Term Debt LongTermDebt	2574000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2018Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	120000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2454000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2455000	USD
CY2018Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2335000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	82000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-120000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-151000	USD
CY2018Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-119000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1308000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-332000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3894000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1681000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2993000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-272000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1207000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1308000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2993000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-272000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1207000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1308000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2993000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-272000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1207000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	6348000	USD
	us-gaap	Operating Expenses OperatingExpenses	12311000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	6544000	USD
	us-gaap	Operating Expenses OperatingExpenses	12398000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1306000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3043000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-267000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1131000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	252000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	72000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	72000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	72000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	36000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	59000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-52000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	332000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	496000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	568000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-119000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-120000	USD
CY2017Q2	us-gaap	Professional Fees ProfessionalFees	480000	USD
	us-gaap	Professional Fees ProfessionalFees	870000	USD
CY2018Q2	us-gaap	Professional Fees ProfessionalFees	681000	USD
	us-gaap	Professional Fees ProfessionalFees	1187000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6408000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6314000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	159000	USD
CY2018Q2	us-gaap	Purchase Obligation PurchaseObligation	5400000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	696000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1405000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	816000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1378000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	719000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	660000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28496000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29703000	USD
CY2017Q2	us-gaap	Salaries And Wages SalariesAndWages	2243000	USD
	us-gaap	Salaries And Wages SalariesAndWages	4703000	USD
CY2018Q2	us-gaap	Salaries And Wages SalariesAndWages	2118000	USD
	us-gaap	Salaries And Wages SalariesAndWages	4234000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	9799000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	18188000	USD
CY2018Q2	us-gaap	Sales Revenue Net SalesRevenueNet	11475000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	21391000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2929000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5333000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2929000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5599000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	182000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	341000	USD
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	377000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	749000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.688
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	57500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	117000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4860157	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4882407	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.00
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.94
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.23
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	37250	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	83000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	26223000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	23571000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	22032000	USD
CY2017Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	38000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	126000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	21574000	USD
CY2017Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	1242000	USD
CY2018Q2	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	439000	USD
CY2018Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	46000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	20000	USD
CY2017Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	30860000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	30860000	shares
CY2018Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	32890000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	32884000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30860000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30860000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32890000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32884000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30860000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30860000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	32890000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	32884000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30860000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30860000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32890000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32884000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other</font><font style="font-family:inherit;font-size:10pt;"> (Topic 350): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash Flows</font><font style="font-family:inherit;font-size:10pt;"> provides guidance on the presentation of restricted cash and restricted cash equivalents, which are now included with cash and cash equivalents when reconciling the beginning and ending cash amounts shown on the statements of cash flows. Using the retrospective transition method required under the standard, the Company has adjusted the presentation of its Condensed Consolidated Statements of Cash Flows for all periods presented. The adoption of ASU No. 2016-18 did not have any other impact on the Company’s Consolidated Financial Statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional detail by financial statement line item of the ASU 2016-18 impact in our Consolidated Statement of Cash Flows for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Pre-Adoption)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASU 2016-18<br clear="none"/>Impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reported</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Post Adoption)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Six Months Ended June 30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash, beginning of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Six Months Ended June 30, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, cash equivalents and restricted cash, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2014-09 (ASC 606), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> became effective for us beginning with the first quarter of 2018, and adopted the new accounting standard using the modified retrospective transition approach. The modified retrospective transition approach recognized any changes from the beginning of the year of initial application through retained earnings with no restatement of comparative periods. We record revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. We will continue to apply our current business processes, policies, systems and controls to support recognition and disclosure under the new standard. Based on the results of the evaluation, we have determined that the adoption of the new standard presents no material impact on our consolidated financial statements. Application of the transition requirements of the new standard did not have a material impact on opening retained earnings.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</font></div></div>

Files In Submission

Name	View Source	Status
0000719135-18-000055-index-headers.html	Edgar Link	pending
0000719135-18-000055-index.html	Edgar Link	pending
0000719135-18-000055.txt	Edgar Link	pending
0000719135-18-000055-xbrl.zip	Edgar Link	pending
bovielogoa01.jpg	Edgar Link	pending
bvx-20180630.xml	Edgar Link	completed
bvx-20180630.xsd	Edgar Link	pending
bvx-20180630_cal.xml	Edgar Link	unprocessable
bvx-20180630_def.xml	Edgar Link	unprocessable
bvx-20180630_lab.xml	Edgar Link	unprocessable
bvx-20180630_pre.xml	Edgar Link	unprocessable
bvx_2018q2x10-q.htm	Edgar Link	pending
bvx_2018q2x10-qexhibit311.htm	Edgar Link	pending
bvx_2018q2x10-qexhibit312.htm	Edgar Link	pending
bvx_2018q2x10-qexhibit321.htm	Edgar Link	pending
bvx_2018q2x10-qexhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2018 Q2 Form 10-Q Financial Statement

#000071913518000055 Filed on August 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2018 Q2 Form 10-Q Financial Statement

#000071913518000055 Filed on August 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx